Cargando…
IL-17 is Aberrantly Overexpressed Among Under-treatment Systemic Lupus Erythematosus Patients
BACKGROUND & OBJECTIVE: Systemic lupus erythematosus (SLE) is an autoimmune disease with chronic inflammatory immune response. Current therapies mostly rely on glucocorticoids which are accompanied by side-effects and mostly fail to achieve a favorable remission. Th17 subpopulation of T cells is...
Autores principales: | Mohammadi, Saeed, Sedighi, Sima, Memarian, Ali |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Iranian Society of Pathology
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6742740/ https://www.ncbi.nlm.nih.gov/pubmed/31583001 http://dx.doi.org/10.30699/ijp.2019.94878.1934 |
Ejemplares similares
-
IL-17 in Systemic Lupus Erythematosus
por: Crispín, José C., et al.
Publicado: (2010) -
Cytokines in Systemic Lupus Erythematosus—Focus on TNF-α and IL-17
por: Richter, Patricia, et al.
Publicado: (2023) -
LncRNA IL21‐AS1 interacts with hnRNPU protein to promote IL21 overexpression and aberrant differentiation of Tfh cells in systemic lupus erythematosus
por: Liu, Limin, et al.
Publicado: (2022) -
Aberrant T Cell Signaling and Subsets in Systemic Lupus Erythematosus
por: Katsuyama, Takayuki, et al.
Publicado: (2018) -
Aberrant B-Cell Activation in Systemic Lupus Erythematosus
por: Kang, Na, et al.
Publicado: (2022)